Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MGNX | MacroGenics, Inc.

IndexRUT P/E40.54 EPS (ttm)0.11 Insider Own0.10% Shs Outstand61.88M Perf Week-6.39%
Market Cap292.74M Forward P/E- EPS next Y-2.23 Insider Trans333.44% Shs Float60.27M Perf Month-11.67%
Income7.40M PEG- EPS next Q-0.09 Inst Own94.50% Short Float / Ratio8.21% / 9.27 Perf Quarter-20.49%
Sales152.50M P/S1.92 EPS this Y42.20% Inst Trans-8.16% Short Interest4.95M Perf Half Y-36.24%
Book/sh2.77 P/B1.64 EPS next Y-1015.00% ROA2.60% Target Price12.38 Perf Year30.84%
Cash/sh3.73 P/C1.22 EPS next 5Y- ROE5.50% 52W Range2.93 - 7.90 Perf YTD-32.34%
Dividend- P/FCF91.48 EPS past 5Y-29.10% ROI-85.50% 52W High-42.53% Beta1.98
Dividend %- Quick Ratio5.60 Sales past 5Y-0.70% Gross Margin93.70% 52W Low54.71% ATR0.28
Employees357 Current Ratio5.60 Sales Q/Q-49.60% Oper. Margin3.00% RSI (14)39.19 Volatility3.84% 5.03%
OptionableYes Debt/Eq0.00 EPS Q/Q237.20% Profit Margin4.90% Rel Volume0.38 Prev Close4.58
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout0.00% Avg Volume534.16K Price4.54
Recom2.00 SMA20-8.82% SMA50-9.49% SMA200-21.91% Volume204,561 Change-0.87%
Date Action Analyst Rating Change Price Target Change
Mar-17-23Downgrade Guggenheim Buy → Neutral
Nov-22-22Downgrade Cowen Outperform → Market Perform
Nov-14-22Upgrade BMO Capital Markets Market Perform → Outperform $5.70 → $16
Jul-18-22Downgrade SMBC Nikko Outperform → Neutral $5
Jul-11-22Downgrade BMO Capital Markets Outperform → Market Perform $31 → $4
May-04-22Downgrade Guggenheim Buy → Neutral
Feb-28-22Upgrade Citigroup Neutral → Buy $23 → $21
Feb-11-22Initiated BMO Capital Markets Outperform $31
Feb-04-22Initiated SMBC Nikko Outperform $40
Nov-17-21Resumed Guggenheim Buy $30
Sep-05-23 07:00AM
Aug-31-23 04:30PM
Aug-19-23 07:40AM
Aug-14-23 11:19AM
Aug-11-23 01:26PM
12:33PM Loading…
Aug-10-23 12:33PM
Aug-09-23 11:30PM
Jul-31-23 05:35PM
Jul-05-23 11:55AM
Jun-28-23 08:12AM
Jun-08-23 07:27AM
08:09AM Loading…
May-14-23 08:09AM
May-10-23 12:10PM
May-09-23 05:25PM
May-05-23 08:27AM
May-04-23 04:30PM
Apr-25-23 10:01AM
Apr-24-23 06:15PM
Apr-07-23 08:48AM
Mar-22-23 01:22PM
Mar-20-23 06:59PM
Mar-18-23 02:52AM
Mar-17-23 06:15PM
12:17PM Loading…
Mar-16-23 12:17PM
Mar-15-23 11:00PM
Mar-14-23 12:32PM
Mar-11-23 07:30AM
Mar-09-23 03:59PM
Mar-08-23 05:36PM
Mar-07-23 06:00PM
Mar-02-23 04:30PM
Feb-20-23 09:56AM
Feb-17-23 06:27AM
Feb-14-23 10:01AM
Feb-13-23 05:20PM
Feb-06-23 04:30PM
Jan-24-23 07:57AM
Jan-06-23 06:15PM
Jan-04-23 05:50PM
Jan-02-23 09:57AM
Dec-29-22 06:51AM
Dec-06-22 08:01AM
Dec-05-22 09:55AM
Dec-02-22 09:35AM
Nov-29-22 12:57PM
Nov-22-22 11:55AM
Nov-18-22 02:54PM
Nov-17-22 06:10PM
Nov-14-22 06:31PM
Nov-09-22 05:31AM
Nov-07-22 06:40PM
Nov-04-22 06:51PM
Nov-03-22 11:30PM
Nov-02-22 04:30PM
Nov-01-22 09:55AM
Oct-26-22 04:30PM
Oct-25-22 10:01AM
Oct-18-22 12:44PM
Oct-17-22 01:04PM
Oct-10-22 03:37PM
Sep-12-22 07:14PM
Sep-02-22 07:00AM
Aug-14-22 08:07AM
Aug-12-22 09:55AM
Aug-09-22 03:23PM
Aug-08-22 05:25PM
Aug-04-22 10:00AM
Aug-01-22 10:01AM
Jul-25-22 04:01PM
Jul-19-22 09:29AM
Jul-12-22 01:56PM
Jul-11-22 12:28PM
Jul-08-22 04:30PM
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 x CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B x CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH TARGET N V10% OwnerSep 07Buy5.26200,0001,052,8409,779,963Sep 11 03:39 PM
HURWITZ EDWARDDirectorAug 30Buy4.9115,00073,65033,074Sep 01 04:06 PM
Peters Jeffrey StuartSenior VP and General CounselMar 10Sale6.035,37232,3930Mar 14 04:22 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 22Option Exercise0.008,75008,750Feb 24 04:35 PM
Bonvini EzioSr VP, Research & CSOFeb 22Option Exercise0.009,3750123,799Feb 24 04:34 PM
BIOTECH TARGET N V10% OwnerFeb 14Buy5.07500,0002,532,6009,579,963Feb 16 12:37 PM
BIOTECH TARGET N V10% OwnerJan 19Buy5.30150,000794,9259,079,963Jan 23 04:21 PM
BIOTECH TARGET N V10% OwnerDec 27Buy5.61200,0001,121,8008,929,963Dec 28 11:03 AM
BIOTECH TARGET N V10% OwnerDec 23Buy5.88200,0001,176,8008,729,963Dec 28 11:03 AM
BIOTECH TARGET N V10% OwnerNov 22Buy5.96300,0001,788,1808,529,963Nov 25 11:37 AM
Risser Eric BlasiusChief Operating OfficerOct 28Option Exercise1.518,50012,83553,468Oct 31 04:36 PM
BIOTECH TARGET N V10% OwnerOct 24Buy4.36250,0001,090,5008,229,963Oct 25 04:19 PM
BIOTECH TARGET N V10% OwnerOct 21Buy4.63250,0001,157,1007,979,963Oct 25 04:19 PM
BIOTECH TARGET N V10% OwnerOct 20Buy4.00285,9771,143,5657,729,963Oct 21 03:03 PM
BIOTECH TARGET N V10% OwnerOct 19Buy3.70168,422623,9197,443,986Oct 21 03:03 PM